Drug intelligence / Profile preview

HGT-Aging-1

Development stage: Preclinical
Lead developer: Houston Gene Therapeutics
Modality: Gene Therapies
Administration: Intravenous

Overview

HGT-Aging-1 is a preclinical-stage gene therapy candidate under development by Houston Gene Therapeutics. The program is aimed at addressing biological aging and other specialty indications. While the specific genetic payload and molecular target have not been disclosed, the therapy utilizes a gene-based approach to potentially modulate pathways involved in the aging process. As of 2024, the asset remains in the early stages of development within the sponsor's pipeline.

Beyond the preview

Go deeper on HGT-Aging-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGT-Aging-1.

Explore the full profile